Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - H.C. Wainwright has reiterated its Buy rating and $35.00 price target on aTyr Pharma (NASDAQ:ATYR) after the company announced the completion of its pivotal Phase 3 EFZO-FIT study. The stock, which has gained over 47% in the past six months despite a recent 10% weekly decline, currently trades at $5.24. According to InvestingPro data, three analysts have revised their earnings upwards for the upcoming period.
On July 22, aTyr Pharma reported that the last patient has completed their final visit in the Phase 3 trial of efzofitimod, the company’s lead therapeutic candidate for pulmonary sarcoidosis, a major form of interstitial lung disease.
The global, randomized, double-blind, placebo-controlled study enrolled 268 patients and was designed to last 52 weeks, with participants randomized equally to receive either 3.0 mg/kg or 5.0 mg/kg intravenous doses of efzofitimod, or placebo, once monthly for a total of 12 doses.
The primary endpoint of the EFZO-FIT study is steroid reduction, with secondary endpoints including measures of lung function and sarcoidosis symptoms, incorporating a forced steroid taper protocol throughout the trial period.
aTyr Pharma is expected to report topline data from the EFZO-FIT study later this quarter, with H.C. Wainwright noting that the trial represents the first-ever global Phase 3 study for patients with sarcoidosis and could potentially address significant clinical demand where conventional treatments are limited or associated with high toxicity risks. With analyst targets ranging from $9 to $35, investors can access detailed financial analysis and 12 additional ProTips through InvestingPro’s comprehensive research reports.
In other recent news, aTyr Pharma has reported positive interim results from its Phase 2 study of efzofitimod for treating systemic sclerosis-related interstitial lung disease (SSc-ILD). The study highlighted clinically significant improvements in patients, with three out of four participants showing notable progress. Additionally, aTyr Pharma is set to be included in the Russell 2000 and Russell 3000 indexes, effective June 27, 2025, marking its recognition among the largest publicly traded U.S. companies. H.C. Wainwright analysts have reaffirmed a Buy rating on aTyr Pharma, maintaining a $35 price target following interim findings from the EFZO-CONNECT study. Leerink Partners also continues to rate aTyr Pharma as Outperform, expressing optimism about the upcoming Phase 3 EFZO-FIT readout for efzofitimod in pulmonary sarcoidosis. Furthermore, aTyr Pharma is advancing its investigational drug candidate, ATYR0101, which will be highlighted at the American Thoracic Society 2025 Respiratory Innovation Summit. The candidate has shown promise in preclinical models for its unique anti-fibrotic properties. These developments reflect aTyr Pharma’s ongoing efforts in advancing its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.